Sudeep Pharma Ltd

Sudeep Pharma Ltd

₹ 699 2.89%
12 Dec - close price
About

Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]

Key Points

Company Overview[1]
Sudeep Pharma Limited is a leading manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company has evolved from producing basic excipients to offering a broad portfolio of over 100 products, serving more than 1,100 customers globally. Its mineral-based ingredients, including calcium, zinc, iron, and magnesium salts, are widely used in formulations across health, nutrition, and food applications.

  • Market Cap 7,892 Cr.
  • Current Price 699
  • High / Low 796 / 631
  • Stock P/E 82.5
  • Book Value
  • Dividend Yield 0.00 %
  • ROCE 28.6 %
  • ROE 25.1 %
  • Face Value 1.00

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 30.0%

Cons

  • Company has high debtors of 166 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
218 345 404 344 357
172 277 315 211 224
Operating Profit 46 68 89 133 133
OPM % 21% 20% 22% 39% 37%
4 8 11 8 8
Interest 1 2 5 4 6
Depreciation 4 4 5 5 6
Profit before tax 45 70 91 132 129
Tax % 22% 26% 26% 26% 26%
35 52 67 98 96
EPS in Rs 248.31 371.23 476.69 696.05 9.85
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 1%
TTM: 4%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 23%
TTM: -2%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 30%
Last Year: 25%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 1 1 1 1 10
Reserves 115 167 235 333 418
31 73 71 60 123
67 92 109 56 54
Total Liabilities 214 333 416 451 604
68 120 90 96 105
CWIP 23 4 26 44 88
Investments 24 15 19 29 32
99 194 282 282 380
Total Assets 214 333 416 451 604

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
36 -5 42 59 59
-45 -28 -41 -41 -92
13 40 -10 -16 54
Net Cash Flow 4 7 -9 2 22

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 97 130 114 150 166
Inventory Days 66 71 115 131 199
Days Payable 73 65 86 99 110
Cash Conversion Cycle 90 136 143 182 255
Working Capital Days 15 37 57 125 140
ROCE % 37% 35% 39% 29%

Shareholding Pattern

Numbers in percentages

14 Recently
Nov 2025
76.16%
1.54%
14.76%
7.54%
No. of Shareholders 2,17,982

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents